Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Fosinopril sodium

SKU: orb1223741

Description

Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.(In Vitro):Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.(In Vivo):Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration.Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number88889-14-9
MW586.65
Purity>98% (HPLC)
FormulaC30H45NO7P·Na
SMILESCCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[Na+]
TargetRAAS
SolubilityEthanol: 4 mg/mL (6.83 mM); Water: 117 mg/mL (199.78 mM)

Bioactivity

In Vivo
Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration. Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model. Animal model: HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g). Dosage: 4.67 mg/kg. Administration: p.o. ; 4 weeks. Result: Against cardiac dysfunction and structural alteration and suppressed apoptosis.
In Vitro
Fosinopril (0, 1, 10, 33, 100 μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2.Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2.Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

SQ 28,555

Similar Products

  • Fosinopril sodium [orb1308486]

    99.37% (May vary between batches)

    88889-14-9

    585.65

    C30H45NO7P·Na

    25 mg, 50 mg, 100 mg, 500 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Fosinopril sodium (orb1223741)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 70.00
10 mg
$ 90.00
25 mg
$ 120.00
50 mg
$ 190.00
100 mg
$ 240.00
200 mg
$ 350.00
500 mg
$ 570.00